MRI and MRS Brain Scans for Brain Mapping in Healthy Subjects
Recruiting in Palo Alto (17 mi)
+1 other location
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: National Institute of Mental Health (NIMH)
Disqualifiers: Axis 1 diagnosis, HIV, Neurological illness, others
No Placebo Group
Approved in 2 Jurisdictions
Trial Summary
What is the purpose of this trial?Background:
- Magnetic resonance imaging (MRI) is a widely used scanning technique to obtain images of the human body and evaluate activity in the brain. A particular MRI method called magnetic resonance spectroscopy (MRS) can be used to study brain chemistry as well, which may help researchers who are studying new treatments for psychiatric illnesses. Researchers are interested in improving current MRI and MRS techniques, as well as developing new MRI and MRS techniques to view and measure brain chemicals and brain activity.
Objectives:
- To implement, develop, and optimize brain chemistry imaging techniques using magnetic resonance imaging and magnetic resonance spectroscopy.
Eligibility:
- Healthy individuals between 18 and 65 years of age.
Design:
* This study will involve a screening visit and a scanning visit at the National Institutes of Health Clinical Center.
* Participants will be screened with a full medical and physical examination, blood and urine tests, and neurological testing.
* During the second visit, participants will have an MRI scan of the brain. (Participants who have received an MRI within the past year will not need to have a second one; the images of the previous scan will be used for this study.) All participants will then have an MRS scan using the same scanning equipment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the study is for healthy individuals without significant medical conditions, it's possible that certain medications might need to be paused. Please consult with the study coordinators for specific guidance.
What data supports the effectiveness of the treatment Magnetic Resonance Spectroscopic Imaging Techniques?
Research shows that Magnetic Resonance Spectroscopic Imaging (MRSI) can provide detailed images of brain metabolites, which helps in analyzing brain metabolism and potentially diagnosing brain diseases early. Proton Magnetic Resonance Spectroscopy (1H MRS) has been useful in studying neurological and psychiatric disorders, with better results at higher magnetic field strengths.
12345Is MRI and MRS brain scanning safe for healthy humans?
MRI and MRS brain scans are generally considered safe for healthy humans, as they are non-invasive techniques widely used in clinical and research settings to evaluate brain metabolism without the use of ionizing radiation.
25678How is this brain mapping treatment different from other treatments?
This treatment uses MRI and MRS brain scans to map brain metabolism in healthy subjects, which is unique because it provides non-invasive insights into brain function without the need for drugs or invasive procedures. Unlike standard imaging techniques, MRS can assess metabolic changes, offering a deeper understanding of brain health.
357910Eligibility Criteria
This trial is for healthy individuals aged 18 to 65 who can consent and lie flat for about two and a half hours. It's not suitable for those with significant lab abnormalities, pregnant or breastfeeding women, people with metallic implants affected by MRI, claustrophobia, HIV positive individuals, substance use disorders, current psychiatric diagnoses or neurological conditions.Inclusion Criteria
Healthy based on medical history and physical exam
I am between 18 and 65 years old.
Able to give written informed consent
+1 more
Exclusion Criteria
Metallic foreign bodies that would be affected by the magnetic resonance imaging (MRI) magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan
Pregnant or breastfeeding
NIMH employees and staff and their immediate family members will be excluded from the study per NIMH policy.
+6 more
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
1 visit
1 visit (in-person)
MRI and MRS Scanning
Participants undergo MRI and MRS scans to evaluate brain and muscle metabolites
1-2 hours
1 visit (in-person)
Follow-up
Participants are monitored for any immediate adverse effects post-scan
1 week
Participant Groups
The study aims to improve brain imaging techniques using magnetic resonance imaging (MRI) and spectroscopy (MRS). Participants will undergo medical exams followed by an MRI scan of the brain and MRS scans to view and measure brain chemicals.
1Treatment groups
Experimental Treatment
Group I: One ArmExperimental Treatment2 Interventions
Subjects receive the same scan
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, MD
National Institutes of Health Clinical CenterBethesda, MD
Loading ...
Who Is Running the Clinical Trial?
National Institute of Mental Health (NIMH)Lead Sponsor
References
Phosphorus magnetic resonance spectroscopic imaging using flyback echo planar readout trajectories. [2018]To present and evaluate a fast phosphorus magnetic resonance spectroscopic imaging (MRSI) sequence using echo planar spectroscopic imaging with flyback readout gradient trajectories.
Flip-angle mapping of 31P coils by steady-state MR spectroscopic imaging. [2015]Phosphorus ((31)P) MR spectroscopic imaging (MRSI) is primarily applied with sensitive, surface radiofrequency (RF) coils that provide inhomogeneous excitation RF field (B1(+)) and rough localization due to their B1(+) and sensitivity (B1(-)) profiles. A careful and time-consuming pulse adjustment and an accurate knowledge of flip angle (FA) are mandatory for quantification corrections.
Comparison of human brain metabolite levels using 1H MRS at 1.5T and 3.0T. [2022]Proton magnetic resonance spectroscopy (MRS) of the human brain has proven to be a useful technique in several neurological and psychiatric disorders and benefits from higher field scanners as signal intensity and spectral resolution are proportional to the magnetic field strength.
[Advance of magnetic resonance spectroscopic imaging (MRSI) techniques]. [2011]Magnetic resonance spectroscopic imaging (MRSI) can provide density images of various metabolites in the human body, in vivo, by utilizing chemical shift. This technique has received attention as a new method for analyzing the diseased state, via metabolism. It increases the accuracy of diagnosis and provides hope for early diagnosis of brain disease. However, because a measurement time of more than ten minutes to one hour is required for imaging, it has been difficult to use MRSI techniques for clinical diagnosis. Improved techniques for high-speed imaging have recently been developed. This review describes the recent advances in this field.
In vivo proton magnetic resonance spectroscopic imaging of the healthy human brain at 9.4 T: initial experience. [2022]In this study, the feasibility of in vivo proton magnetic resonance spectroscopic imaging ((1)H MRSI) of the healthy human brain at a field strength of 9.4 T, using conventional acquisition techniques, is examined and the initial experience is summarized.
Proton magnetic resonance spectroscopy in the brain: report of AAPM MR Task Group #9. [2022]AAPM Magnetic Resonance Task Group #9 on proton magnetic resonance spectroscopy (MRS) in the brain was formed to provide a reference document for acquiring and processing proton (1H) MRS acquired from brain tissue. MRS is becoming a common adjunct to magnetic resonance imaging (MRI), especially for the differential diagnosis of tumors in the brain. Even though MR imaging is an offshoot of MR spectroscopy, clinical medical physicists familiar with MRI may not be familiar with many of the common practical issues regarding MRS. Numerous research laboratories perform in vivo MRS on other magnetic nuclei, such as 31P, 13C, and 19F. However, most commercial MR scanners are generally only capable of spectroscopy using the signals from protons. Therefore this paper is of limited scope, giving an overview of technical issues that are important to clinical proton MRS, discussing some common clinical MRS problems, and suggesting how they might be resolved. Some fundamental issues covered in this paper are common to many forms of magnetic resonance spectroscopy and are written as an introduction for the reader to these methods. These topics include shimming, eddy currents, spatial localization, solvent saturation, and post-processing methods. The document also provides an extensive review of the literature to guide the practicing medical physicist to resources that may be useful for dealing with issues not covered in the current article.
MR spectroscopy and spectroscopic imaging of the brain. [2021]Magnetic resonance spectroscopy (MRS) and the related technique of magnetic resonance spectroscopic imaging (MRSI) are widely used in both clinical and preclinical research for the non-invasive evaluation of brain metabolism. They are also used in medical practice, although their ultimate clinical value continues to be a source of discussion. This chapter reviews the general information content of brain spectra and commonly used protocols for both MRS and MRSI and also touches on data analysis methods and quantitation. The main focus is on proton MRS for application in humans, but many of the methods are also applicable to other nuclei and studies of animal models as well.
(1)H spectroscopic imaging of human brain at 3 Tesla: comparison of fast three-dimensional magnetic resonance spectroscopic imaging techniques. [2021]To investigate the signal-to-noise-ratio (SNR) and data quality of time-reduced three-dimensional (3D) proton magnetic resonance spectroscopic imaging ((1)H MRSI) techniques in the human brain at 3 Tesla.
Lesion-Specific Metabolic Alterations in Relapsing-Remitting Multiple Sclerosis Via 7 T Magnetic Resonance Spectroscopic Imaging. [2023]Magnetic resonance spectroscopic imaging (MRSI) of the brain enables in vivo assessment of metabolic alterations in multiple sclerosis (MS). This provides complementary insights into lesion pathology that cannot be obtained via T1- and T2-weighted conventional magnetic resonance imaging (cMRI).
Comparison of single voxel brain MRS AT 3T and 7T using 32-channel head coils. [2019]The purpose of this study was to compare magnetic resonance spectroscopy (MRS) of three different regions of the human brain between 3 and 7 Tesla, using the same subjects and closely matched methodology at both field strengths.